EIKN Eikon Therapeutics, Inc.
$5.55▲ +0.09%
Healthcare
Other
After hours
$5.55▲ +0.00%
Oct 27, 4:25 PM ET
Volume 697.2K
Avg Volume (10D) 505.0K
Key Metrics & Fundamentals
Market Cap
$300.35M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.44 - 17.40
% vs 50 MA
-38.08%
% vs 200 MA
–%
RSI-14
29.5
MACD Histogram
-0.0900
Beta (1Y vs SPY)
1.98
Free Cash Flow
-$65.21M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$88.34M
COGS
–
Operating Exp
$93.39M
Operating Income
-$93.39M
EBIT
-$93.39M
Pretax Income
-$88.41M
Net Income
-$88.41M
EPS (Diluted)
-1.63
Price & Volume History
Loading chart…
Recent News
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
GlobeNewswire · Oct 26, 2026 6:00 AM ET
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
GlobeNewswire · Oct 23, 2026 9:15 AM ET
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
GlobeNewswire · Oct 18, 2026 6:05 PM ET
HC Wainwright Initiates Coverage on Eikon Therapeutics With Buy Rating, $23 Price Target
MT Newswires · Oct 16, 2026 7:27 AM ET
Eikon Therapeutics Files IND for Prostate Cancer Drug EIK1006
MT Newswires · Oct 15, 2026 9:11 AM ET
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
GlobeNewswire · Oct 15, 2026 8:00 AM ET
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
GlobeNewswire · Sep 3, 2026 7:30 AM ET
Eikon Therapeutics to Participate in Investor Conferences in September 2026
GlobeNewswire · Aug 26, 2026 7:30 AM ET
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
MarketBeat · Aug 22, 2026 7:01 AM ET
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
GlobeNewswire · Aug 18, 2026 4:15 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See EIKN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.